SecBot SecBot
Biotech Drug Report Generated Aug 28, 2026

gotistobart

BNTX·BioNTech SE
NEUTRAL
Drug Impact Rating6/10
Trial phase
Phase 3
Time to market
At least 2-4 years away from potential approval, assuming positive Phase 3 data leads to regulatory filing. The PRESERVE-003 Phase 3 trial is ongoing with updated OS data due Sept 2026, but no regulatory submission has been announced.
Why 6/10
The next hard, dated catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. This is ~2 weeks away, and gotistobart is a significant but not the sole late-stage asset in BioNTech's broad pipeline, warranting a 6.
Actionable Insight NEUTRAL

The key near-term catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. Positive data could drive BNTX shares higher, but gotistobart is one of several late-stage assets in BioNTech's broad pipeline, so the stock impact is unlikely to be binary.

Price Chart

Loading chart...

Executive Summary

Gotistobart is an oncology immunotherapy drug from BioNTech SE (BNTX, Nasdaq), being evaluated in a Phase 3 trial (PRESERVE-003) for squamous non-small cell lung cancer and a Phase 2 trial (PRESERVE-004) for platinum-resistant ovarian cancer. At the European Lung Cancer Congress 2026, gotistobart demonstrated a 54% reduction in risk of death in squamous NSCLC. The next major catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial will be presented. BioNTech has a broad late-stage oncology pipeline with 25+ Phase 2/3 trials, and analyst consensus is strongly bullish (22 buy/strong buy ratings, mean price target $121). However, the company is still pre-commercial in oncology, posting net losses as COVID vaccine revenue declines.

How It Works

Gotistobart is an oncology immunotherapy agent being developed by BioNTech. While its exact molecular target is not fully detailed in public disclosures, it is designed to stimulate the immune system to attack cancer cells. It is being studied in non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer.

Trial Status

Gotistobart is being evaluated in the Phase 3 PRESERVE-003 trial for squamous non-small cell lung cancer (updated OS data to be presented at WCLC Sept 12-15, 2026) and the Phase 2 PRESERVE-004 trial for platinum-resistant ovarian cancer (data presented at ASCO 2026). At ELCC 2026, gotistobart showed a 54% reduction in risk of death in squamous NSCLC.

The Two-Sided Case

▲ Bull Case4
At the European Lung Cancer Congress 2026, gotistobart showed a 54% reduction in risk of death in squamous NSCLC, a strong efficacy signal that supports the ongoing Phase 3 PRESERVE-003 trial.
Updated overall survival data from the Phase 3 PRESERVE-003 trial will be presented at WCLC 2026 (Sept 12-15), providing a near-term catalyst within ~2 weeks.
BioNTech has a deep late-stage oncology pipeline with 25+ Phase 2/3 trials including 13 pivotal studies, and analyst consensus is strongly bullish (22 analysts: 22 buy/strong buy, 0 sell, mean price target $121 implying ~26% upside).
Institutional accumulation is evident, Fidelity added 32.6% to its BNTX position in Q2 2026, Goldman Sachs doubled, D.E. Shaw doubled, and Point72 opened a new position.
▼ Bear Case4
Gotistobart's mechanism of action is not well-characterized in public disclosures, making it harder to assess competitive differentiation vs. established checkpoint inhibitors and other immunotherapies in NSCLC.
BioNTech's oncology pipeline is broad but pre-commercial; the company posted a €531.9M GAAP net loss in Q1 2026 and its COVID vaccine revenue continues to decline, meaning pipeline setbacks carry more weight.
Institutional activity is mixed, Citadel, Jane Street, and Bank of America trimmed BNTX positions in Q2 2026, while FINRA short-volume ratio recently exceeded 0.30, indicating elevated short-selling flow.
The Phase 3 PRESERVE-003 data at WCLC is an updated OS readout, not a definitive registrational filing; even strong data may not immediately lead to regulatory submission.

Upcoming Catalysts

  • WCLC 2026 (Sept 12-15, 2026): Updated overall survival data from Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BioNTech SE 6-K BNTX ·Originating report

Sources · 4

Hover a chip for the title
1 globenewswire.com2 globenewswire.com3 sec.gov4 sec.gov